SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies

We summarize here in vitro evidences of efficacy for convalescent plasma, currently approved vaccines and monoclonal antibodies against SARS-CoV-2 variants of concern (VOC: B.1.1.7, B.1.351, P.1, and B.1.617.2), variants of interest (VOI: B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, and B.1.671.1),...

Full description

Saved in:
Bibliographic Details
Published in:Viruses 2021-06, Vol.13 (7), p.1211
Main Authors: Focosi, Daniele, Tuccori, Marco, Baj, Andreina, Maggi, Fabrizio
Format: Article
Language:English
Subjects:
convalescent plasma
COVID-19
immune escape
Immunotherapy
Infections
Monoclonal antibodies
mRNA vaccines
Mutation
mutations
neutralizing antibody
Plasma
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We summarize here in vitro evidences of efficacy for convalescent plasma, currently approved vaccines and monoclonal antibodies against SARS-CoV-2 variants of concern (VOC: B.1.1.7, B.1.351, P.1, and B.1.617.2), variants of interest (VOI: B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, and B.1.671.1), and other strains (B.1.1.298 and B.1.258delta). While waiting from real world clinical efficacy, these data provide guidance for the treating physician.
ISSN:1999-4915
1999-4915
DOI:10.3390/v13071211